Skip to main
PRCT
PRCT logo

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics has demonstrated a positive trend in utilization growth, averaging approximately 6.1% per quarter over the past six quarters, indicating increasing adoption of its surgical robotics systems. The company's strategic decision to manage operating expenses at half the rate of top-line growth suggests a disciplined approach to achieving profitability, reflecting investor confidence in its financial management. Additionally, a strong performance in capital system placements, with 58 new systems installed in the recent quarter, surpassing prior guidance, further underscores the company's robust market position and growth potential in the urology sector.

Bears say

PROCEPT BioRobotics has experienced a significant decline in its stock, dropping approximately 54% year-to-date, indicating persistent challenges despite the company's ability to exceed its own guidance. Key factors contributing to the negative outlook include a potential decrease in demand for capital equipment, reduced handpiece usage by customers, heightened competitive pressure, and uncertainties surrounding reimbursement practices for Aquablation therapy. Additionally, anticipated adjustments to sales forecasts for 2026 and negative post-market performance reflect concerns over utilization rates and inventory levels.

PRCT has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 8 analysts, PRCT has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.